AlphaCentric Advisors’s VYNE Therapeutics VYNE Stock Holding History

AlphaCentric Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-268,485	Closed	-$505K	–	286
2024 Q3	$505K	Sell	268,485 -42,015	-14%	-$79.6K	0.38%	74
2024 Q2	$612K	Sell	310,500 -134,500	-30%	-$335K	0.45%	71
2024 Q1	$1.37M	Sell	445,000 -223,151	-33%	-$481K	0.82%	47
2023 Q4	$1.56M	Buy	+668,151	New	+$2.08M	1.05%	32

Other funds holding VYNE

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AlphaCentric Advisors's VYNE Position: Q4 2024 in Review

AlphaCentric Advisors sold out of VYNE Therapeutics (VYNE) in Q4 2024, closing a stake of 268,485 shares — an estimated $505K sold.

AlphaCentric Advisors first reported a position in VYNE in Q4 2023 and held it in 4 quarters. The position peaked at $1.56M in Q4 2023. 35 funds tracked by Wall St. Rank hold VYNE as of Q4 2024.

AlphaCentric Advisors reported no remaining VYNE Therapeutics position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 268,485 VYNE Therapeutics shares in Q4 2024, an estimated $505K.
AlphaCentric Advisors first reported a position in VYNE Therapeutics in Q4 2023 and held it in 4 quarters.
AlphaCentric Advisors's VYNE Therapeutics position peaked at $1.56M in Q4 2023.
35 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.